| Literature DB >> 28342444 |
Jakub Sikora1, Shaalee Dworski2, E Ellen Jones3, Mustafa A Kamani4, Matthew C Micsenyi5, Tomo Sawada5, Pauline Le Faouder6, Justine Bertrand-Michel6, Aude Dupuy6, Christopher K Dunn4, Ingrid Cong Yang Xuan7, Josefina Casas8, Gemma Fabrias8, David R Hampson7, Thierry Levade9, Richard R Drake3, Jeffrey A Medin10, Steven U Walkley11.
Abstract
Farber disease is a rare autosomal recessive disorder caused by acid ceramidase deficiency that usually presents as early-onset progressive visceral and neurologic disease. To understand the neurologic abnormality, we investigated behavioral, biochemical, and cellular abnormalities in the central nervous system of Asah1P361R/P361R mice, which serve as a model of Farber disease. Behaviorally, the mutant mice had reduced voluntary locomotion and exploration, increased thigmotaxis, abnormal spectra of basic behavioral activities, impaired muscle grip strength, and defects in motor coordination. A few mutant mice developed hydrocephalus. Mass spectrometry revealed elevations of ceramides, hydroxy-ceramides, dihydroceramides, sphingosine, dihexosylceramides, and monosialodihexosylganglioside in the brain. The highest accumulation was in hydroxy-ceramides. Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types (eg, neurons, endothelial cells, and choroid plexus cells), most notably microglia and/or macrophages. Coalescing and mostly perivascular granuloma-like accumulations of storage-laden CD68+ microglia and/or macrophages were seen as early as 3 weeks of age and located preferentially in white matter, periventricular zones, and meninges. Neurodegeneration was also evident in specific cerebral areas in late disease. Overall, our central nervous system studies in Asah1P361R/P361R mice substantially extend the understanding of human Farber disease and suggest that this model can be used to advance therapeutic approaches for this currently untreatable disorder.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28342444 PMCID: PMC5397689 DOI: 10.1016/j.ajpath.2016.12.005
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307